Seek Returns

AMGN vs. GMAB: Amgen vs. Genmab Stock Comparison

How do Amgen (AMGN) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Amgen (AMGN) and Genmab (GMAB) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Amgen (AMGN) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Amgen (AMGN) and Genmab (GMAB)
Profile ItemAMGNGMAB
NameAmgen Inc. Common StockGenmab A/S American Depositary Shares
Country/RegionUnited StatesDenmark
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization249.05 billion USD32.98 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 17, 1983June 1, 2009
Security TypeCommon StockADR

Price Performance

Cumulative Growth

AMGN
GMAB
GSPC
Loading price history…
Amgen (AMGN) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Amgen (AMGN) and Genmab (GMAB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Amgen (AMGN) and Genmab (GMAB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Amgen (AMGN) and Genmab (GMAB)
MetricAMGNGMAB
Total Return (1Y)48.82%91.17%
Total Return (3Y, Annualized)24.31%20.70%
Total Return (5Y, Annualized)20.67%3.98%

Risk Profile

Drawdown History

AMGN
GMAB
GSPC
Loading price history…
Amgen (AMGN) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Amgen (AMGN) and Genmab (GMAB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Amgen (AMGN) and Genmab (GMAB)
MetricAMGNGMAB
Volatility (1Y, Annualized)29.12%45.68%
Beta (5Y)0.430.72
Max Drawdown (5Y)-24.86%-61.79%
Avg. Volume (3M)2.76M4.09M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
AMGN and GMAB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Amgen (AMGN) and Genmab (GMAB)
MetricAMGNGMAB
Sharpe Ratio (1Y)1.531.90
Sortino Ratio (1Y)2.363.82

Profitability

ROE (TTM)

Both Amgen (AMGN) at 78.35% and Genmab (GMAB) at 12.07% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

78.35%

Max
109.18%
AMGN
78.35%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max
109.18%
GMAB
12.07%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Amgen (AMGN) at 24.14% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.14%

AMGN
24.14%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max
18.05%
GMAB
16.97%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Amgen (AMGN) at 35.79% and Genmab (GMAB) at 37.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.79%

Max
83.12%
AMGN
35.79%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.15%

Max
83.12%
GMAB
37.15%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Amgen (AMGN) and Genmab (GMAB)
MetricAMGNGMAB
ROE (TTM)78.35%12.07%
ROA (TTM)8.91%8.24%
Net Margin (TTM)24.14%16.97%
Operating Margin (TTM)35.79%37.15%
Gross Margin (TTM)72.47%92.67%

Growth

Revenue Growth

Both Amgen (AMGN) at 9.95% and Genmab (GMAB) at 19.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Amgen (AMGN) at 88.23% sits in the top EPS growth quartile, while Genmab (GMAB) at -9.23% is closer to the peer norm — faster per-share earnings growth for AMGN.

Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Amgen (AMGN) and Genmab (GMAB)
MetricAMGNGMAB
Revenue Growth (YoY)9.95%19.19%
Revenue Growth (3Y CAGR)11.77%21.23%
EPS Growth (YoY)88.23%-9.23%
EPS Growth (3Y CAGR)5.52%8.48%

Financial Strength

Current Ratio (MRQ)

Both Amgen (AMGN) at 1.48 and Genmab (GMAB) at 2.45 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.48

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
AMGN
1.48
Min
0.10

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GMAB
2.45
Min
0.10
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but AMGN is more stretched: Genmab (GMAB) at 0.82 sits in the higher-leverage quartile and Amgen (AMGN) at 3.76 is above its industry benchmark range.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.76

AMGN
3.76
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max
1.42
GMAB
0.82
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Amgen (AMGN) and Genmab (GMAB)
MetricAMGNGMAB
Current Ratio (MRQ)1.482.45
Debt / Equity (MRQ)3.760.82
Net Debt / EBITDA2.312.45

Dividends

Dividend Yield (TTM)

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a yield of 2.16%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.16%

AMGN
2.16%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Genmab (GMAB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Amgen (AMGN) reports a payout of 57.62%, ranking against industry peers normally.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.62%

AMGN
57.62%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Amgen (AMGN) and Genmab (GMAB)
MetricAMGNGMAB
Dividend Yield (TTM)2.16%0.00%
Dividend Payout Ratio (TTM)57.62%0.00%

Valuation

P/E Ratio (TTM)

Amgen (AMGN) at 26.69 is near its industry’s usual P/E ratio, while Genmab (GMAB) at 45.84 sits in the richer quartile — GMAB needs stronger growth or earnings quality to justify the premium.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.69

Max
85.34
Q3
43.46
AMGN
26.69
Median
26.69
Q1
13.30
Min
0.07

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.84

Max
85.34
GMAB
45.84
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Amgen (AMGN) at 6.40 and Genmab (GMAB) at 7.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.40

Max
58.18
Q3
25.77
Median
7.30
AMGN
6.40
Q1
3.01
Min
0.01

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.68

Max
58.18
Q3
25.77
GMAB
7.68
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Genmab (GMAB) at 5.36 sits near its industry’s typical P/B ratio, while Amgen (AMGN) at 17.35 prices above its benchmark range — AMGN looks rich relative to book.

AMGN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.35

AMGN
17.35
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.36

Max
13.53
Q3
6.54
GMAB
5.36
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Amgen (AMGN) vs. Genmab (GMAB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Amgen (AMGN) and Genmab (GMAB)
MetricAMGNGMAB
P/E Ratio (TTM)26.6945.84
P/S Ratio (TTM)6.407.68
P/B Ratio (MRQ)17.355.36
Free Cash Flow Yield (TTM)2.96%2.59%